M&A / Deals Biogen uplifts rare disease pipeline with $5.6bn Apellis buyout Pharmaceutical TechnologyBiogen's acquisition of Apellis Pharmaceuticals will add Syfovre and Empaveli to the latter company's portfolio of medicines.M&A / DealsRare DiseaseRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaceutical Technology Biogen’s acquisition of Apellis Pharmaceuticals will add Syfovre and Empaveli to the latter company’s portfolio of medicines. M&A / DealsRare DiseaseRead full story Post navigation Previous: Telomir seeks FDA approval for Telomir-1 to treat breast cancerNext: Agios mulls early FDA filing for sickle cell therapy Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026